These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27492836)

  • 21. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 22. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus).
    P Brock A; Isaza R; Egelund EF; Hunter RP; Peloquin CA
    J Vet Pharmacol Ther; 2014 Oct; 37(5):472-9. PubMed ID: 24684601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An interlaboratory quality control programme for the measurement of tuberculosis drugs.
    Aarnoutse RE; Sturkenboom MG; Robijns K; Harteveld AR; Greijdanus B; Uges DR; Touw DJ; Alffenaar JW
    Eur Respir J; 2015 Jul; 46(1):268-71. PubMed ID: 25882800
    [No Abstract]   [Full Text] [Related]  

  • 29. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
    Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
    Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lambert LA; Ijaz K; Navin TR
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
    [No Abstract]   [Full Text] [Related]  

  • 32. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
    Hao LH; Guo SC; Liu CC; Zhu H; Wang B; Fu L; Chen MT; Zhou L; Chi JY; Yang W; Nie WJ; Lu Y
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1505-12. PubMed ID: 25517820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
    Shrivastava P; Gautam L; Sharma R; Dube D; Vyas S; Vyas SP
    J Microencapsul; 2021 Mar; 38(2):108-123. PubMed ID: 33267623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development.
    Susanto BO; Wicha SG; Hu Y; Coates ARM; Simonsson USH
    Clin Pharmacol Ther; 2020 Aug; 108(2):274-286. PubMed ID: 32080839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetic bases for the drug-free prevention of drug-induced hepatitis in pulmonary tuberculosis patients].
    Koriakin VA; Sokolova GB; Ziia AV; Zeliger LR; Ivleva AIa
    Ter Arkh; 1987; 59(7):75-7. PubMed ID: 3672366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of reduced bioavailability of rifampicin.
    Joshi SR
    J Assoc Physicians India; 1999 Sep; 47(9):943-4. PubMed ID: 10778683
    [No Abstract]   [Full Text] [Related]  

  • 40. Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis.
    Cojutti P; Giangreco M; Isola M; Pea F
    Int J Antimicrob Agents; 2017 Jul; 50(1):23-28. PubMed ID: 28495479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.